Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients
- 3 October 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 43 (1), 29-38
- https://doi.org/10.1080/07435800.2017.1373662
Abstract
Purpose: This study aimed to investigate the role of sclerostin and dkk1 in the bone metabolism of type 2 diabetic patients. Methods: This cross-sectional study included 95 inpatients with type 2 diabetes mellitus. We divided the patients into three groups (i.e., the normal bone mineral density (BMD) group, osteopenia group and osteoporosis group) based on their different BMD levels and measured the serum levels of sclerostin, dkk1, 25-hydroxyvitamin D3 (25OHD3), bone turnover markers and other biochemical data in each group. Results: Significantly increased levels of serum sclerostin and dkk1 were found in the osteoporosis group, even when the male and female cohorts were considered separately. Ordinal logistic regression analysis suggested that the levels of serum sclerostin were independently associated with the presence of osteopenia and osteoporosis after adjusting for age, gender and 25OHD3 (sclerostin: OR = 1.02, p = 0.001). The areal BMDs were negatively correlated with the levels of serum sclerostin and dkk1 and positively correlated with 25OHD3. In addition, age, glycosylated hemoglobin and serum sclerostin levels were predictors for N-terminal propeptide of type 1 procollagen and serum dkk1 levels were the only predictors for crosslinked carboxyterminal telopeptide in type 1 collagen. Conclusions: The sclerostin and dkk1 levels increased in conjunction with the reduction of BMD, confirming that the Wnts, inhibited by sclerostin and dkk1, were potentially responsible for bone fragility in type 2 diabetes patients with osteoporosis. Note that the serum sclerostin levels were predictors for bone formation, while the DKK1 levels predicted bone resorption.Keywords
Funding Information
- Hebei Provincial Health Bureau (GL2011-43)
This publication has 48 references indexed in Scilit:
- Hypovitaminosis D and incidence of obesity: a prospective studyEuropean Journal of Clinical Nutrition, 2013
- Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitusJournal of Bone and Mineral Research, 2012
- Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 DiabetesJAMA, 2011
- Sclerostin levels during growth in childrenOsteoporosis International, 2011
- Bone structure and turnover in type 2 diabetes mellitusOsteoporosis International, 2011
- Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanismJournal of Bone and Mineral Research, 2011
- Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 2010
- Dickkopf-1 Promotes Hyperglycemia–Induced Accumulation of Mesangial Matrix and Renal DysfunctionJournal of the American Society of Nephrology, 2010
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women.JCI Insight, 1996